Advertisement
- United States
- /
- Biotech
- /
- NasdaqGS:CGON
CG Oncology Full Year 2024 Earnings: Misses Expectations
CG Oncology (NASDAQ:CGON) Full Year 2024 Results
Key Financial Results
- Net loss: US$88.0m (loss widened by 30% from FY 2023).
- US$1.41 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
CG Oncology Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 18%. Earnings per share (EPS) also missed analyst estimates by 8.8%.
Looking ahead, revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 2.3% from a week ago.
Risk Analysis
You should learn about the 2 warning signs we've spotted with CG Oncology.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:CGON
CG Oncology
A late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer.
Adequate balance sheet with low risk.
Market Insights
Advertisement
Weekly Picks
ST
stuart_roberts on Unicycive Therapeutics ·
Looking to be second time lucky with a game-changing new product
Fair Value:US$21.5371.2% undervalued
29 followersusers have followed this narrative
0 commentsusers have commented on this narrative
5 likesusers have liked this narrative
HE
HegelBayeBagel on PlaySide Studios ·
PlaySide Studios: Market Is Sleeping on a Potential 10M+ Unit Breakout Year, FY26 Could Be the Rerate of the Decade
Fair Value:AU$0.8465.5% undervalued
6 followersusers have followed this narrative
1 commentusers have commented on this narrative
3 likesusers have liked this narrative
AN
AnimalDoctorKwon on Inotiv ·
Inotiv NAMs Test Center
Fair Value:US$1.275.7% undervalued
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
3 likesusers have liked this narrative
TH
TheValueDetector on Cognyte Software ·
This isn’t speculation — this is confirmation.A Schedule 13G was filed, not a 13D, meaning this is passive institutional capital, not acti
Fair Value:US$95.6792.6% undervalued
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Recently Updated Narratives
UN
unknown on Gold Fields ·
Beyond the "Value Trap"—Defending the $50 Intrinsic Floor
Fair Value:US$64.219.8% undervalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
UN
unknown on State Street SPDR S&P 500 ETF Trust ·
The Concentration Trap: Why the S&P 500 Is No Longer a 'Safe' Diversifier
Fair Value:US$58915.9% overvalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AL
alex30free on ITAB Shop Concept ·
Transformational Merger
Fair Value:SEK 44.8566.2% undervalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Popular Narratives
DA
davidlsander on Ubisoft Entertainment ·
Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share
Fair Value:€33.887.4% undervalued
59 followersusers have followed this narrative
5 commentsusers have commented on this narrative
25 likesusers have liked this narrative
AN
AnalystConsensusTarget on Microsoft ·
Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks
Fair Value:US$603.2234.2% undervalued
1277 followersusers have followed this narrative
2 commentsusers have commented on this narrative
9 likesusers have liked this narrative
AN
AnalystConsensusTarget on NVIDIA ·
NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
Fair Value:US$253.0226.9% undervalued
1073 followersusers have followed this narrative
6 commentsusers have commented on this narrative
32 likesusers have liked this narrative
Trending Discussion
US
User on Tesla ·
This article completely disregards (ignores, forgets) how far China is in this field. If Tesla continues on this path, they will be fighting for their lives trying to sell $40000 dollar robots that can do less than a $10000 dollar one from China will do. Fair value of Tesla? It has always been a hype stock with a valuation completely unbased in reality. Your guess is as good as mine, but especially after the carbon credit scheme got canned, it is downwards of $150.
4
|0
US
User on Tesla ·
There is a lot of Musk's puffery being echoed in this article. "ecosystem dominance", Tesla certainly do not dominate any of their new markets. If Tesla is the undisputed leader of the premium "Closed Garden.", it is only through EV's and that business has been declining year-on-year, despite the market increasing. Vehicle manufactures are finding that customers are rejecting the subscription model. "The Cybercab fleet (launching 2026) acts as the financial bridge.", that is a stretch. Even if Level 4/5 autonomy is achieved, "profitability" still has to be proved, where the competition is not necessarily Waymo, but Uber. Taking the driver out of a ride‑hailing service may not be the killer saving people think it will be. Likewise, outside of CGI and for quite some time, an Optimus humanoid robot may prove more expensive and not as useful, versatile, skilled and knowledgeable as a domestic worker. Telsa may be withdrawing from the EV market, but for its other ventures, they have arrived late to the party, do not lead and show no sign that they will dominate any of them.
2
|0